Multiple antitumor modalities may be necessary to overthan unmodified parental tumor cells. The in vivo growth come lung tumor-mediated immunosuppression and effecof ex vivo modified L1C2 cells was evaluated. There was tively treat non-small cell lung cancer (NSCLC). To evalua dose-response relationship between the amount of IL-7 ate a multimodality gene therapy approach for control of secreted in vitro and the growth of genetically modified local tumor growth, a weakly immunogenic murine alveolar murine tumor in vivo. Transduced tumor cells regressed in cell carcinoma, L1C2, was transduced with either the mice following GCV therapy. Although ex vivo gene modiinterleukin-7/hygromycin-herpes simplex thymidine kinase fication of tumor cells led to complete resolution of the (IL-7/HyHSVtk) internal ribosome entry site (IRES) retrovitumor following implantation in vivo, IL-7 and HSVtk gene ral vector or a vector containing the HyHSVtk, but not the modified tumor cells were not effective in treating estab-IL-7 gene. Of the many cytokines available for gene translished parental tumors. However when 5 × 10 5 bone marfer, IL-7 was chosen for these studies because it both row-derived, in vitro activated dendritic cells (DC) were stimulates CTL responses and down-regulates tumor proadministered in combination with transduced tumor and duction of the immunosuppressive peptide TGF-␤. Follow-GCV, 5 day old established tumors were eradicated in 80% ing selection in hygromycin, IL-7 transduction was conIntroduction vaccine because they have defects in antigen processing Lung cancer is the leading cause of cancer death in the and presentation and produce immune inhibitory cyto-USA. 1 Several new treatment strategies are in developkines. 12 An ideal antitumor vaccine would contain a ment because overall 5-year survival is less than 15%. [2] [3] [4] [5] source of immunopotentiating cytokine, activated proLung cancer has been unresponsive to immunotherapy fessional antigen presenting cells (APC) and a source of with systemic recombinant cytokine administration or tumor antigen. In the present study, the system adoptive transfer of activated lymphocytes. 6, 7 This may developed to address tumor-mediated immune deficits be due in part to local immunosuppression induced by includes autologous tumor cells transduced ex vivo with lung tumors, but systemic administration of cytokines a polycistronic retroviral vector containing both IL-7 and can only partially reverse lung tumor-mediated immunoHyHSVtk genes. IL-7 was utilized in the current study suppression. [8] [9] [10] Transfer of cytokine genes into tumor because it has the capacity to both stimulate CTL activity cells is a strategy for cytokine delivery that can augment and to decrease the tumor's production of the potent tumor immunogenicity. 11 However, lung tumor cells may immunosuppressive cytokine TGF-␤. 13, 14 In addition, we have found that IL-7 gene transfer in human NSCLC can augment tumor expression of MHC class I, ICAM-1, expression of FAS and this results in increased tumor cell proliferative capacity in vitro (Figure 2a )compared to the HyHSVtk transduced or parental L1C2 cells. sensitivity to apoptosis. 16 Thus, IL-7 has several immunepotentiating activities that may be of particular benefit in
The bicistronic vector used in this study contains the HSVtk gene. Cells expressing HSVtk are sensitized to the lung cancer therapy.
The third component of the therapeutic system is cotoxic effects of GCV. 20 The GCV sensitivity of the genetically modified cells was assessed by the MTT assay. In administration of syngeneic bone marrow-derived, ex vivo activated dendritic cells. Dendritic cells, the most comparison to the parental L1C2 cells, both the HyHSVtk and IL-7/HyHSVtk-transduced cells were exquisitely potent antigen-presenting cells, maintain a high-level expression of the adhesion and costimulatory molecules sensitive to the toxic effects of GCV (Figure 2b ). Following exposure to GCV (10 m), HyHSVtk and ILcritical for T cell dependent immune responses. 17 Hence, immunization with dendritic cells in combination with 7/HyHSVtk-transduced tumor cells showed a significant decrease in survival compared to parental L1C2 cells (P cytokine-transduced tumor cells has the advantage of supplying potent Ag presentation in the presence of cyto-Ͻ 0.05). An additional measure of HSVtk function is the capacity of transduced cells to mediate the bystander kine-activated cytotoxic T lymphocytes (CTL). The central importance of functional APC in the immune effect. The bystander effect refers to the capacity of HSVtk-transduced cells to mediate killing of nontransresponse against cancer was well defined in recent studies by Huang et al. 18 These investigations reveal that even duced cells which are in physical proximity. 21 This may occur via the transfer of apoptotic bodies and/or the highly immunogenic tumors require host APC for antigen presentation. Thus host APC, rather than tumor cells, passage of phosphorylated GCV products via gap junctions. [21] [22] [23] Consistent with a functional bystander effect, present tumor antigen. These findings are consistent with the known defects in human lung cancer: lung cancer when mixed with HyHSVtk or IL-7/HyHSVtk transduced cells, parental L1C2 cells were sensitive to the toxic cells lack critical portions of the requisite antigen processing and presentation pathways functioning in proeffects of GCV (50 m) (Figure 2c ). Parental L1C2 cells were more sensitive to the toxic effects of GCV as the fessional APC. 12 The rationale for using ex vivo activated dendritic cells in this setting is further supported by studpercentage of transduced cells in the mixing ratio increased. As few as 10% transduced cells in the mixture ies indicating that tumor cells produce peptides that interfere with dendritic cell function and maturation. 19 had the capacity to sensitize parental cells to the toxic effects of GCV. The combination of these therapeutic components at the tumor site can lead to heightened specific immune responses by supplementing cytokine production and Dose responsive decrement in tumorigenicity of transduced cells in vivo: IL-7-HSVtk transduction effective antigen presentation which have been found to be deficient in lung cancer. 12 decreases tumorigenicity and increases immunogenicity To determine the in vivo behavior of ex vivo transduced In this study we report that: (1) the IL-7/HyHSVtk IRES vector effectively and coordinately delivers the L1C2 tumor cells, transduced cells were inoculated s.c. in BALB/C mice. The low IL-7 (1.25 ng/ml/10 6 cells per 24 active cytokine and drug sensitivity genes to a murine alveolar carcinoma cell line; and (2) that gene-modified h) secreting L1C2 cells formed tumors and were lethal in all mice. There was a dose-response relationship between murine alveolar carcinoma cells used in combination with GCV and dendritic cells effectively eradicate 5-daythe amount of IL-7 secreted and the number of mice rejecting the tumor. Clones producing intermediate old established tumors in vivo while promoting long-term specific antitumor immunity.
amounts of IL-7 (5 ng/ml/10 6 cells per 24 h) were rejected in 60% of mice, whereas high IL-7 (10 ng/ml/10 6 cells per 24 h) producing clones were rejected in all mice Results (Table 1) .
Subcutaneous inoculations of 5 × 10 4 parental L1C2 cells were tumorigenic in 100% of mice. Administration Functional in vitro evaluation of transduced genes expressed by the bicistronic vector in L1C2 cells of GCV (2 mg i.p. twice daily for 4 days) to mice bearing parental L1C2 did not significantly affect in vivo tumor Bicistronic vectors have the advantage of coordinate expression of two genes (Figure 1 ). To determine if both growth ( Figure 3 ). In contrast, administration of GCV to mice bearing HyHSVtk or IL-7/HyHSVtk-modified the cytokine and drug sensitivity genes were functional in transduced cells, we assessed the biological activity of tumors resulted in their complete regression. The effect tumor-derived IL-7 and GCV sensitivity of tumor cells in vitro. Following retrovirus-mediated IL-7 transduction of L1C2 alveolar carcinoma cells and selection in hygromycin, IL-7 secreted in the medium was determined by murine IL-7-specific ELISA. L1C2-IL-7 clones produced 1.25-10 ng of IL-7/ml/10 6 cells per 24 h. To determine if tumor-derived IL-7 was biologically active syngeneic splenic lymphocytes were cultured in cell free supernatants from IL-7-transduced tumor cells. Compared to IL-7/HyHSVtk-transduced tumor cells had a decreased of GCV in mice bearing IL-7/HyHSVtk-transduced with a mixing ratio of 50:50 and all mice rejected tumors with a mixing ratio of 90:10). In the absence of GCV administration mixing the high IL-7 producing clone with parental cells in ratios of 50:50 and 90:10, lead to 40 modified tumor cells, mice that had rejected the following tumors L1C2-IL-7/HyHSVtk, L1C2-IL-7/HyHSVtk + and 60% rejection respectively. All mice rejected the tumor with a 50:50 ratio of IL-7/HyHSVtk transduced to GCV, L1C2-HyHSVtk + GCV or irradiated parental L1C2 cells were rechallenged with 5 × 10 4 parental cells. Eighty parental tumor cell and GCV administration ( Table 2) .
To determine the immunogenicity of the genetically per cent of mice that initially rejected the L1C2-IL-lished mice were treated with either GCV or diluent injections ( Figure 4 ). Parental tumors grew in SCID mice and ganciclovir had no effect on the growth of the parental cells. HyHSVtk vector modified cells grew in SCID mice but on GCV administration, the growth of the HyHSVtk vector modified cells was significantly reduced and survival of the mice extended. The L1C2-IL-7/HyHSVtk cells grew more slowly than the parental L1C2 or L1C2-HyHSVtk cells in the SCID mice and the survival of the mice bearing the L1C2-IL-7/HyHSVtk tumors was extended compared to control. Growth of L1C2-IL-7/HyHSVtk tumors was further reduced in SCID mice on ganciclovir treatment and mice in this group had the longest survival. However, in contrast to immunocompetent BALB/C mice, there were no complete antitumor responses in SCID mice and all mice in each group eventually died due to progressive tumor growth.
Combined gene therapy for the treatment of established tumors in vivo: dendritic cells enable complete HSVtk/GCV or combination gene therapy with IL-7/ HSVtk/GCV failed to control tumor growth. We postulated that therapeutic failure in this setting could be due 7/HyHSVtk cells were able to reject parental tumor cells on rechallenge while 75% of mice from the L1C2 IL-7 + GCV group rejected parental tumors on rechallenge (Table 3) . In contrast only 25% of mice from both the L1C2-HyHSVtk + GCV or the irradiated control groups were able to reject the rechallenge dose of parental L1C2 tumors. or L1C2-IL-7/HyHSVtk and after tumors were estab- nate expression of both genes. 24 The ex vivo retroviral L1C2-IL-7 + GCV 9/12 transduction of lung tumor cells for vaccine gene therapy
Rejection of transduced tumors in vivo requires intact

Discussion
in this system has the following advantages. First, the currently employed for standard drug therapy regimens. The level of cytokine production can be controlled either by cloning tumor cells for cytokine production, as in the current study, or by increasing the number of cells deliv- malignancy). In addition, tumor cell death induced in this manner could lead to the release of tumor antigens, previously unrecognized by the host, thereby augmenting activation of specific host antitumor immunity and Only those therapies which resulted in complete response against metastatic disease. Current studies in responses were associated with splenocyte production of our laboratory address the potential for this form of ther-GM-CSF and IFN␥. The greatest production of GM-CSF apy to treat metastatic disease. and IFN␥ was obtained from splenocytes of mice receivAfter finding that the IL-7/HyHSVtk vector was funcing IL-7/HyHSVtk tumors + DC + GCV (Table 5) .
tionally active in the transduced murine lung tumor cell line, the tumorigenicity of the genetically modified cells was determined in syngeneic BALB/C mice. Parental to have anti-tumor effects in vivo. 27, 28 We have previously DC + GCV 227 ± 2 0 IL-7 + DC + GCV 1078 ± 100 660 ± 7
found that IL-7-transduced fibrosarcoma tumors were Control 0 0 heavily infiltrated with host T cells which appeared to be responsible for tumor regression. 27 However, as indicated production of TGF␤. 13,14,29 Our current and previous studies also suggest that IL-7 directly decreases tumor determined which cytokines are optimal for this type of therapy, especially given the possibility that each type of proliferation. 15 Transduced tumor cells maintained their GCV sensiprimary tumor may have a different immunoregulatory response to a given cytokine. We have chosen to focus on tivity in vivo as inoculation of HyHSVtk or IL-7/HyHSVtk modified L1C2 cells combined with GCV administration IL-7 for NSCLC for the following reasons. IL-7, originally described as a growth factor for pre-B cells, 34 has been led to complete rejection of the genetically modified tumors. In fact, admixture of IL-7-producing tumor cells found to stimulate the growth of thymocytes and mature T cells. 35 Resting T cells proliferate in direct response to with parental nontransduced cells led to tumor reduction even without GCV administration. This could be due to IL-7, as well as through an IL-2-dependent pathway. 36 In addition, IL-7 enhances the generation of cytotoxic T one or more of several mechanisms: (1) a transduced tumor-mediated bystander effect; 25 (2) an IL-7-mediated cells 37 and LAK cells, 38 and induces cytokine secretion and tumoricidal activity in human peripheral blood monimmune response; 27, 28 and/or (3) an IL-7-mediated antiproliferative response. 15 The bystander effect was also ocytes. 29 The co-stimulatory molecule B7 can be induced on T cells by IL-7. 39 Because activated T cells can cooperational in vivo and was increased when IL-7 was produced from admixed tumor cells. These findings suggest express both B7 and its counter-receptor, CD28, this suggests that IL-7-activated T cells may be capable of that high levels of IL-7 secreted at the tumor site by IL-7-modified tumors is sufficient for tumor rejection when autocrine costimulation via the CD28 activation pathway. 40 IL-7 synergizes with IL-12 in the induction of T a fraction of the tumor mass is genetically modified.
Long-term systemic immunity was generated in mice cell proliferation, cytotoxicity, and IFN-␥ release. 41 IL-7 may contribute to this synergy by up-regulating IL-12R that had rejected IL-7/HyHSVtk-modified L1C2 cells or HyHSVtk and IL-7/HyHSVtk + GCV. Mice that had expression. In agreement with these findings are recent studies indicating that IL-7 plays a role in cell-mediated rejected genetically modified tumor cells were able to reject 10 times the TD/LD50 dose. The IL-7 component immune responses characteristic of type 1 cytokines 42 and enhances Ag-specific T cell cytotoxicity. 43 In human of the vector contributed predominantly to long-term systemic effects since vaccination with IL-7/HyHSVtk modi-NSCLC cells, we found that IL-7 transduction slowed the in vitro proliferation of tumor cells and augmented surfied cells led to protection in 80% on rechallenge whereas vaccination with HyHSVtk modified cells plus GCV led face molecule expression of MHC class I and ICAM-1. 15 This suggests that IL-7 may enhance the immunogenicity to protection in only 25% of mice. To determine the importance of a cell-mediated immune component of NSCLC cells. In addition, allogeneic peripheral blood lymphocytes co-cultured with IL-7-transduced human involved in the rejection of genetically modified tumors in immunocompetent BALB/C mice, the tumorigenicity tumor cells showed enhanced cytolytic and proliferative capacities compared to co-culture with parental cells. 15 of the genetically modified tumor cells was tested in SCID mice. IL-7/HyHSVtk-modified L1C2 cells grew IL-7 can potentiate the growth and production of IFN-␥ from tumor-reactive TIL. 44 This is important because IFNslowly in SCID mice and prolonged survival was evident. Proliferation of the genetically modified cells in SCID ␥ production has been found to be requisite for TIL antitumor efficacy. When used in adoptive transfer, IL-7-genmice was further reduced and survival of mice increased when the mice bearing genetically modified cells were erated CTL have been shown to reduce metastatic tumor as effectively as do CTL generated in IL-2. 37 In accordtreated with GCV. However, all mice eventually died secondary to tumor growth. This suggests that the complete ance with these findings, IL-7 has been suggested both as an additional cytokine for the in vitro expansion of rejection of IL-7-modified tumor cells requires intact host immunity but non-T cell-mediated pathways for inhilymphocytes for adoptive transfer 23, 24 and as a systemic agent for cancer immunotherapy. 38 We and others 27, 45 bition of tumor growth are operative. In this study we found that effective in vivo therapy of have found that IL-7 mediates significant antitumor responses in vivo in murine models. 28, 46 In addition, we established lung cancer required replacement of each of the immune components known to be deficient at the have found that IL-7 down-regulates both macrophage 47 and tumor 13, 14 production of TGF-␤, a potent inhibitor of lung tumor site. The lung tumor environment is known to be a rich source of immune inhibitory cytokines 10, 30, 31 antitumor immunity. Although we focused on IL-7 in this study, other cytokines may also be efficacious when used and both lymphocytes and APC are known to be defective. Tumor-infiltrating lymphocyte activities are in this multicomponent system. Because it directly stimulates APC activities and differentiation, we also evaluated depressed and lung tumors have been found to have decreased MHC expression and antigen-processing GM-CSF as the cytokine component in preliminary studies. We found that IL-7 was significantly more effective defects. [8] [9] [10] 12, [30] [31] [32] The use of both IL-7 and HSVtk in a tumor cell vaccine could have the following advantages.
than GM-CSF in this system (data not shown). Dendritic cells are characterized by high-level First, IL-7 activates the local host response and reverses tumor-mediated immunosuppression. After this actiexpression of costimulatory molecules and the potent capacity to present antigen and prime naive CTL in vitro vation has begun, administration of GCV causes lysis of transduced tumor cells and release of tumor antigens in and in vivo. 17, 48, 49 Several recent studies have shown the successful use of peptide pulsed dendritic cells to treat the setting of IL-7-induced heightened antitumor immunity. By injecting the vaccine at the tumor site, the added established tumors or reduce metastases. 50, 51 This therapy utilizes antigen-pulsed dendritic cells with either prebenefit of the bystander effect can augment the local immune response, causing more tumor lysis and the viously identified tumor peptide antigens, acid-elutriated peptides or tumor RNA. 18, [50] [51] [52] [53] In this study we found potential of more antigen presentation by activated antigen-presenting cells co-administered at the tumor site.
that in vitro activated bone marrow-derived DC had the capacity to facilitate the eradication of an established, A variety of cytokines have been used in studies of gene therapy with tumor cells.
33 It has not yet been weakly immunogenic murine alveolar cell carcinoma when combined with IL-7/HyHSVtk-transduced autologRetroviral construct and transduction of tumor cell lines The IL-7 retroviral vector backbone is derived from ous tumor. Immunization with dendritic cells in the setting of cytokine-transduced tumor cells has the advanMoloney murine leukemia virus (MoMLV) (Figure 1) . 64, 65 Both the murine IL-7 cDNA and the hygromycin-herpes tage of restoring potent tumor-antigen presentation which cannot be mediated by the tumor alone. 18 The simplex thymidine kinase fusion genes are driven by the retrovirus LTR and there is an internal ribosomal entry presence of all these components at the tumor site can lead to heightened specific immune responses. Accordsite in the vector construct that allows translation of multiple reading frames from a polycistronic message. 23 The ingly we found that the successful treatment of established tumors with this multicomponent therapy was control vector construct contains the hygromycin gene selectable marker and the HSVtk gene but lacks the accompanied by resistance to tumor rechallenge and an enhanced release of splenocyte IFN-␥ and GM-CSF. The murine IL-7 cDNA. 15 release of these cytokines in response to autologous tumor has been found to be indicative of specific T cellTransduction L1C2 cell line was maintained in exponential growth mediated antitumor responses. 54, 55 Thus this therapy resulted in complete antitumor responses without the use phase in 25-cm 2 T flasks and transduction was performed using retroviral supernatants at a multiplicity of infection or knowledge of specific tumor antigens. This may be important because, although tumor antigens have been of 4:1 in the presence of protamine sulfate (10 g/ml, Sigma, St Louis, MO, USA). After 24 h, the medium was identified in human lung cancer, they are present in a minority of tumors and are recognized only in associreplaced with CM and the cells were incubated for an additional 24 h. The cells were then transferred to a 75-ation with certain specific HLA haplotypes.
56,57
In summary, we have developed a model system to cm 2 flask and grown to confluency. Supernatants were collected from the bulk transduced cells and IL-7 protein evaluate genetic modulation of the autologous tumor to serve as an antigen source and immune enhancer for DC.
was measured by cytokine-specific ELISA. After bulk transduction of L1C2 cells with the IL-7 retroviral vector Gene-modified tumors may enhance the induction of antitumor immunity by augmenting antigen presentation the cells produced 300-500 pg/ml/10 6 cells per 24 h. The IL-7/HyHSVtk and HyHSVtk transduced cells were and CTL activation. Thus, the genetic manipulation of the autologous tumor can act to enhance the generation of selected in 800 g/ml of hygromycin for 10 days. After selection in hygromycin the bulk selected IL-7-transantitumor immunity and serve as the source of antigen for DC. In contrast to conventional immunization with duced cells produced 5 ng/ml/10 6 cells per 24 h. The IL-7-transduced cells were cloned for IL-7 production by purified peptide Ag, autologous tumor has the capacity to provide the activated DC access to the entire repertoire limiting dilution and several clones were isolated that produced 1 to 10 ng of IL-7/ml/10 6 cells per 24 h. of available antigens. This could increase the likelihood of a response and reduce the potential for tumor resistance due to phenotypic modulation.
Isolation and in vitro propagation of dendritic cells Lymphocyte-depleted mouse bone marrow cells were The use of gene therapy or cytokine immunotherapy to control local tumor growth in non-small cell lung cancultured with murine GM-CSF (2 ng/ml) and IL-4 (20 ng/ml) (R&D, Minneapolis, MN, USA) for 8 days as precer has been the focus of recent clinical trials and preclinical studies have shown the efficacy of several gene therviously reported. 50, 52 Medium was replenished every other day. On day 8, nonadherent dendritic cells were apy combinations. 30, [58] [59] [60] [61] [62] Utilization of multicomponent vaccine therapies may allow control of local tumor isolated by pipetting. The dendritic cells were counted, washed twice in PBS and 5 × 10 5 cells injected at the growth and promote specific systemic antitumor responses in lung cancer.
tumor site. Consistent with previous studies, dendritic cells characterized by flow cytometry were found to have high-level expression of: B7-1, B7-2, CD11c and MHC II
Materials and methods
and to be Ͼ90% dendritic cells (data not shown). Mice IL-7, IFN␥ and GM-CSF ELISA Pathogen-free female BALB/C mice (H-2 d ) (8-12 weeks IL-7 protein concentrations from transduced superof age) were obtained from NIH and Simenson Laboranatants were determined by IL-7-specific ELISA as pretories (Gilroy, CA, USA). Mice were maintained in the viously described. 15 Briefly, 96-well Costar (Cambridge, West LA VA Animal Research Facility. BALB/C SCID MA, USA) plates were coated overnight with 2 g/ml mice were obtained from UCLA and maintained in cages of anti-IL-7 mAb (Genzyme, Cambridge, MA, USA). The housed in laminar flow hoods under pathogen-free wells of the plate were blocked with 10% fetal bovine conditions. serum (Gemini Bioproducts) in PBS for 30 min. The plate was then incubated with the antigen for 1 h and excess Cell culture Line 1 alveolar cell carcinoma (L1C2) was used to estabantigen was washed off with PBS/Tween. The plate was incubated with 1 g/ml of mAb to IL-7 (R&D) for 30 min lish the in vivo model. This is a weakly immunogenic, natural killer cell-resistant, and highly malignant tumor and excess antibody was washed off with PBS/Tween. The plate was incubated with biotinylated anti-goat IgG with minimal metastatic potential, which arose spontaneously in a female BALB/C mouse. 63 The cells were (Zymed, South San Francisco, CA, USA) for 30 min and excess antibody washed off with PBS/Tween. The plate cultured in RPMI (Irvine Scientific, Santa Ana, CA, USA) supplemented with 10% fetal calf serum (Gemini Bioprowas incubated with avidin peroxidase and following incubation in OPD substrate the subsequent change in ducts, Calabasas, CA, USA), antibiotics (penicillin and streptomycin) (complete medium (CM) ) and kept at 37°C color was read at 490 nm with a Dynatech MR5000 spectrophotometer (Chantilly, VI, USA). The recombinant ILin a humidified atmosphere containing 5% CO 2 .
7 used in the assay as a standard was obtained from Genmodified cells were inoculated in the right suprascapular area of BALB/C mice and GCV was administered i.p. (2 zyme. Sensitivity of the IL-7 ELISA was 50 pg/ml. For IFN␥ and GM-CSF determinations, the above procedure mg per dose, twice daily for 4 days). Tumor growth and survival were monitored. Mice that had rejected genetiwas repeated but with either IFN␥ or GM-CSF antibody pairs and standards from Pharmingen (San Diego, CA, cally modified tumor cells were rechallenged 30 days following tumor rejection with 5 × 10 4 parental L1C2 cells USA). The sensitivity of the IFN␥ and GM-CSF ELISA was 15 pg/ml. by s.c. inoculation on the left flank. Tumor volumes were monitored three times per week. Tumor proliferation in vitro The MTT assay was performed to determine the proliferIn vivo evaluation of the bystander effect ation rate of the parental, HyHSVtk and IL-7/HyHSVtk
To determine the effect of in vivo mixing on the growth transduced L1C2 cell lines. The cell lines to be tested of parental L1C2 tumors, exponentially growing parental were maintained in exponential growth prior to inoculatcells were mixed with HyHSVtk and IL-7/HyHSVtking 96-well plates for growth rate determination by the transduced L1C2 cells and 10 5 cells were inoculated in the MTT assay as previously described. 66 Briefly, 10 3 cells right suprascapular area. Mixing ratios were as follows: were inoculated in a volume of 200 l in 96-well plates 0:100, 10:90, 50:50, 90:10 and 100:0. Mice were treated and each day 25 l of MTT (5 mg/ml) was added to the with or without GCV (2 mg/ml per dose, twice daily for wells and incubated at 37°C for 4 h. The plates were cen-4 days) and tumor sizes monitored three times per week. trifuged for 10 min at 1000 g and the medium discarded. hensive Cancer Center, American Lung Association, Department of Veterans Affairs, the Helen Neufeld Lymphocyte proliferation
Research Career Development Award (Stop Cancer Splenocytes were isolated from normal mice using a stanAward) and National Institutes of Health grant CA71818. dard protocol. 67 10 5 Cells in 100 l of CM were incubated Sherven Sharma is a recipient of a Research Award from in 96-well plates with 100 l of medium from exponenthe American Lung Association of California and was tially growing parental, HyHSVtk transduced and IL-7/ supported by NIH Institutional Training Grant in PulHyHSVtk transduced L1C2 cells. Murine recombinant ILmonary Medicine HL07014 and a Parker B Francis Fel-7 (10 ng/ml) was used as a control. On day 7, the lymlowship Award of the Francis Families Foundation. Min phocytes were pulsed with 1 Ci of tritiated thymidine Huang was supported by the NIH Institutional Training (Amersham, Arlington Heights, IL, USA; specific activity Grant in Tumor Immunology CA09120. Marina Stolina 62 Ci/mm) for 6 h and the cells were harvested using a was supported by NIH Institutional Training Grant in Skatron cell harvester (Skatron, Sterling, VA, USA) on to Pulmonary Medicine HL07014. Steven Dubinett is a filter mats. The discs were air dried, placed in scintilCareer Investigator of the American Lung Association. lation vials with 1 ml of scintillation fluor and then counted in a Beckman scintillation counter (Fullerton, CA, USA). nentially growing L1C2 parent, control vector and IL-7
